Five breast cancer treatment advances in 2026 expand therapeutic options while raising questions.
News|Podcasts|August 21, 2023
Pharmacy Focus: Oncology Edition - PARP Inhibitors Are Changing the Game in Prostate Cancer
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona.
Advertisement
This month, we spoke with Cassia Griswold, PharmD, a clinical oncology pharmacist at Mayo Clinic Arizona. Griswold discussed the latest updates from ASCO in PARP inhibitors for prostate cancer, as well as what's on the horizon in this quickly-evolving treatment space.
Interested in learning more? Check out this related content:
FDA Approves New Combination Therapy for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer Image-Guided Adaptive Radiation Treatments May Reduce Short-Term Adverse Effects in Patients With Prostate Cancer Compared to Non-Adaptive Treatments Enzalutamide Combination, Monotherapy Reduced the Risk of Metastasis or Death in High-Risk Patients With Prostate Cancer
Advertisement
Related to this article
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
3
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
4
Finerenone in Heart Failure: Evidence and Practice a Year Later
5